GeneCapture brings commercial voice to CDC with AdvaMedDX

Chief Scientist Paula Koelle joined the AdvaMedDx CDC Visit Focused on Barriers to Patient Access discussion regarding diagnostic testing policies. The purpose of the discussion was to bring the voice of commercial companies to the CDC. AdvaMedDx led a delegation of 17 clinical and scientific experts to the CDC in Atlanta to meet with senior leadership and clinical staff from the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP) and the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). They discussed the importance of diagnostics testing policies, guidelines, guidances and recommendations – including those generated by the CDC, staying current with innovation to improve patient access to critical diagnostic technologies.

The meeting also featured dialogue on the important role of diagnostics stewardship in combating antimicrobial resistance. AdvaMedDx appreciates the CDC’s interest in diagnostics stewardship, including agency plans to host a dedicated forum for various government agencies, industry and academia on this important matter. AdvaMedDx has shared with the CDC the association’s inpatient diagnostic stewardship recommendations.

Finally, the day included a discussion of the mission and purview of the newly created Tri-Agency Task Force for Emergency Use Diagnostics. The CDC, CMS and the FDA are the task force members. Among other issues, AdvaMedDx members encouraged the CDC to leverage the task force to improve issues known to be challenges associated with access to diagnostic testing during a declared public health emergency.

AdvaMedDx is working with members and the CDC to continue these discussions.